Top searches



B2RLaw advises Auxilius Pharma on capital raise to fuel groundbreaking growth to the US market


B2RLaw advised Auxilius Pharma Sp. z o.o. and its founders on a venture capital transaction related to the investment of Cofounder Zone Corporate Angel Fund ASI, AUGEBIT Closed Investment Fund, and several business angels and current partners at Auxilius.

With the new funds, the Company will be able to further develop its flagship  project involving introduction of a Value Added Medication cardiological drug to the US market, as well as other drug development projects.

Auxilius Pharma was founded by Jędrzej Litwiniuk and Uwe Tigör in 2019 and is a fast-growing pharmaceutical early stage company with a focus on further developing and optimizing medications well established in some markets but not in others. The Company is currently focused on the development of cardiovascular medicine which is available in the EU but not in the US. Auxilius Pharma has reformulated the drug into a once-daily product in an effort to improve convenience and compliance of patients. Earlier this year, the Company get the nod of the American Food and Drug Administration (FDA) for the clinical development plan of its cardiovascular drug. The Agency agreed to use an expedite, 505(b)2 regulatory pathway for the product, which will allow a speedy and cost-effective regulatory pathway.

B2R’s team was led by Krystyna Jakubowska (Advocate, Senior Associate), who was supported by Teresa Pilecka-Juda (Attorney-at-law, Senior Associate) and Magdalena Zawiślak (Junior Associate). Rafal Stroiński (Advocate, Senior Partner) oversaw B2R’s team. SSW Pragmatic Solutions advised Cofounder Zone, who was represented by Tomasz Goliński and Michał Sioda.

Krysia Jakubowska advises, “we are extremely pleased to have assisted Auxilius Pharma on this exciting transaction. With Poland being one of global leaders in cardiac treatment, it is pleasing to advise on a transaction which provides Auxilius and its founders with the funds which will allow it to continue developing its cardiovascular drug with the view of bringing this effective medication to US patients and clinicians. ”

View more resources

Catch up on the very latest B2RLAW
announcements and news here.


B2RLaw on a New York expedition!

Embarking on an exciting trip to NYC to deepen ties and explore synergies between the US and Poland! B2RLaw will […]


B2RLaw recommended in the Legal 500 EMEA ranking 2024

We are proud to announce that in this year’s edition of The Legal 500 we have been recommended in 8 categories […]


Andrzej Zając speaks at “Poland’s Energy Evolution: Understanding EU Regulations”

Today Andrzej Zając (Advocate, Partner, Head of Real Estate & Energy) was the speaker at “Poland’s Energy Evolution: Understanding EU Regulations” webinar. Andrzej […]


Danyila Zubach at Ukrainian Private Equity & Venture Capital Summit

Today you can meet Danyila Zubach (UA Advocate, Junior Associate) at “Ukrainian Private Equity & Venture Capital Summit”. This is the EU-Ukraine […]


Record High Damages for LGBTQ+ Victim

B2RLaw actively encourages all its lawyers to partake in ProBono work. We are pleased to share news about this successful […]


Pre-Moot session at B2RLaw’s Warsaw office!

Practice makes perfect! University of Warsaw Willem C. Vis Moot Team in a clash with Vis Moot Team Vilnius during a Pre-Moot session at […]


Get in touch

Not sure who to contact? Let us help you find the right lawyer.

This site uses cookies to improve your experience More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.